TRICHLORMETHIAZIDE W/ RESERPINE
Clinical safety rating: safe
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
Trichlormethiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased blood pressure. Reserpine is an adrenergic neuron blocking agent that depletes catecholamines from peripheral sympathetic nerve endings, reducing peripheral vascular resistance and lowering blood pressure.
| Metabolism | Trichlormethiazide is not extensively metabolized; excreted unchanged in urine. Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation. |
| Excretion | Trichlormethiazide: Renal elimination of unchanged drug (70-80%) and minor biliary/fecal excretion; Reserpine: Renal elimination of metabolites (~60%) and fecal excretion (~40%) with <1% excreted unchanged. |
| Half-life | Trichlormethiazide: 2-3 hours (clinical context: requires multiple daily dosing for sustained diuresis); Reserpine: 50-100 hours (terminal half-life, prolonged due to enterohepatic circulation and tissue binding, leading to sustained antihypertensive effect and risk of accumulation with repeated dosing). |
| Protein binding | Trichlormethiazide: ~78% bound to serum albumin; Reserpine: ~95% bound to plasma proteins (primarily albumin and lipoproteins). |
| Volume of Distribution | Trichlormethiazide: 0.2-0.4 L/kg (confined primarily to extracellular fluid, consistent with low tissue penetration); Reserpine: 9-10 L/kg (extensive tissue binding, particularly to adipose and brain, contributing to prolonged duration). |
| Bioavailability | Trichlormethiazide: Oral bioavailability ~70% (undergoes first-pass metabolism); Reserpine: Oral bioavailability ~50% (extensive first-pass metabolism with hepatic extraction ratio ~0.5). |
| Onset of Action | Oral administration: Trichlormethiazide diuresis begins within 2 hours; Reserpine antihypertensive effect begins within 3-6 days (gradual onset due to slow depletion of catecholamines). |
| Duration of Action | Trichlormethiazide: Diuretic effect lasts 18-24 hours (supports once-daily dosing); Reserpine: Antihypertensive effect persists for 1-2 weeks after discontinuation due to slow recovery of catecholamine stores. |
Oral: 1 tablet (containing 2 mg trichlormethiazide and 0.1 mg reserpine) once daily, with a maximum of 2 mg trichlormethiazide and 0.2 mg reserpine daily.
| Dosage form | TABLET |
| Renal impairment | CrCl <30 mL/min: contraindicated. CrCl 30-50 mL/min: use with caution and consider dose reduction. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution; consider dose reduction. Child-Pugh Class C: contraindicated. |
| Pediatric use | Not recommended; safety and efficacy not established. |
| Geriatric use | Start at lowest dose (e.g., 1 tablet daily); monitor for hypotension, electrolyte disturbances, and CNS effects. Avoid use in frail elderly with depression or significant bradycardia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
| FDA category | Animal |
| Breastfeeding | Both thiazides and reserpine are excreted in breast milk. Thiazides can suppress lactation, while reserpine may cause infant respiratory depression, bradycardia, and nasal congestion. M/P ratio not established. Use during breastfeeding is not recommended; if used, monitor infant for adverse effects. |
| Teratogenic Risk | First trimester: Thiazide diuretics are generally not associated with major malformations, but reserpine may increase risk of neonatal respiratory depression and hypothermia. Second and third trimesters: Use may cause fetal or neonatal jaundice, thrombocytopenia, electrolyte imbalance, and hypotension. Reserpine crosses placenta and may cause respiratory depression, bradycardia, and nasal congestion in neonates. Avoid in pregnancy-induced hypertension because of decreased placental perfusion. |
■ FDA Black Box Warning
Reserpine has been associated with an increased risk of breast cancer in epidemiological studies; however, causal relationship is unclear. Use caution in patients with history of psychiatric depression, as reserpine may exacerbate or precipitate depression.
| Common Effects | Depression |
| Serious Effects |
["Anuria (Trichlormethiazide)","Sulfonamide allergy (since thiazides are sulfonamide derivatives)","History of mental depression (Reserpine)","Active peptic ulcer disease (Reserpine)","Concurrent electroconvulsive therapy","Pheochromocytoma","Hypersensitivity to any component"]
| Precautions | ["May cause electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia)","May precipitate gout or hyperuricemia","May increase blood glucose and lipid levels","Reserpine may cause mental depression, peptic ulcer activation, and bradycardia","Caution in patients with impaired renal or hepatic function"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, electrolytes, renal function, and fluid balance. Monitor fetal growth and amniotic fluid volume. In neonates, monitor for respiratory depression, bradycardia, jaundice, thrombocytopenia, and electrolyte disturbances. |
| Fertility Effects | Limited data. Reserpine may cause amenorrhea or galactorrhea due to prolactin elevation, potentially affecting fertility. Thiazides may not directly impair fertility but can affect electrolyte balance and overall health. Clinical significance unknown. |